Sibutramine (SBT)
Sibutramine is well absorbed from the GI tract (77%), but undergoes considerable first-pass metabolism, reducing its bioavailability. The drug itself reaches its peak plasma level after 1 hour and has also a half-life of 1 hour. Sibutramine is metabolized by cytochrome P450 isozyme CYP3A4 into two pharmacologically-active primary and secondary amineswith half-lives of 14 and 16 hours, respectively. Sibutramine is a neurotransmitter reuptake inhibitor that reduces the reuptake of serotonin (by 53%), norepinephrine (by 54%), and dopamine (by 16%), thereby increasing the levels of these substances in synaptic clefts and helping enhance satiety; the serotonergic action, in particular, is thought to influence appetite. Older anorectic agents such as amphetamine and fenfluramine force the release of these neurotransmitters rather than affecting their reuptake.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Sibutramine (SBT) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Sibutramine (SBT) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Sibutramine (SBT) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Sibutramine (SBT) CLIA Kit Customized Service Offer
n/a ELISA Kit for Sibutramine (SBT) ELISA Kit Customized Service Offer